In Silico prediction of mutant HIV-1 proteases cleaving a target sequence

Jensen, Jan Halborg; Willemoës, Martin; Winther, Jakob R.; De Vico, Luca

Published in:
P L o S One

DOI:
10.1371/journal.pone.0095833

Publication date:
2014

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Jensen, J. H., Willemoës, M., Winther, J. R., & De Vico, L. (2014). In Silico prediction of mutant HIV-1 proteases cleaving a target sequence. P L o S One, 9(5), [5]. https://doi.org/10.1371/journal.pone.0095833
**In Silico** Prediction of Mutant HIV-1 Proteases Cleaving a Target Sequence

Jan H. Jensen¹, Martin Willemoes², Jakob R. Winther², Luca De Vico¹*  

¹ Department of Chemistry, University of Copenhagen, Copenhagen, Denmark, ² Department of Biology, University of Copenhagen, Copenhagen, Denmark

---

**Abstract**

HIV-1 protease represents an appealing system for directed enzyme re-design, since it has various different endogenous targets, a relatively simple structure and it is well studied. Recently Chaudhury and Gray (Structure (2009) 17: 1636–1648) published a computational algorithm to discern the specificity determining residues of HIV-1 protease. In this paper we present two computational tools aimed at re-designing HIV-1 protease, derived from the algorithm of Chaudhury and Gray. First, we present an energy-only based methodology to discriminate cleavable and non-cleavable peptides for HIV-1 proteases, both wild type and mutant. Secondly, we show an algorithm we developed to predict mutant HIV-1 proteases capable of cleaving a new target substrate peptide, different from the natural targets of HIV-1 protease. The obtained in silico mutant enzymes were analyzed in terms of cleavability and specificity towards the target peptide using the energy-only methodology. We found two mutant proteases as best candidates for specificity and cleavability towards the target sequence.

---

**Introduction**

Proteases represent a class of enzymes ubiquitous in all living organisms, with multiple applications in industry and biotechnology research [1–3]. There is thus interest in designing new proteases capable of cleaving specific peptide sequences [4]. HIV-1 protease (PR) represents an attractive starting structure for directed enzyme re-design, since it is known to cleave a variety of sequences. PR is the enzyme responsible for processing the gag–pol fusion polyproteins of the HIV virus [5]. PR is an aspartic protease [6–8] and is a homodimer where each chain is composed of 99 residues. Wild type PR (WT-PR) is very specific for the endogenous cleavage sequences of the polyprotein (endogenous substrate peptides, Table S1 in File S1), even if the source of this specificity is still not completely clear. A series of other non-endogenous peptides have also been found to be cleaved by PR. The latest hypothesis on the origin of this specificity, called dynamic substrate envelope [9,10], states that peptides fitting into the protease cavity through a certain number of hydrogen bonds will be bound and possibly cleaved nearly regardless of their amino acid composition. In fact, there is no clear trend in amino acid sequence (e.g. a negatively charged amino acid in position P1 or a hydrophobic one in position P2). This suggests that with few mutations PR could be made to cleave other target peptide sequences in a specific manner.

Many computational studies on PR, both wild type (WT) and drug resistant mutant enzymes, are aimed at elucidating the affinity of the enzymes towards endogenous substrates and inhibitors to be used as drug candidates [11–14]. Recently Chaudhury and Gray [13] published a computational algorithm specifically tailored for PR and aimed at the identification of the specificity determining residues. The algorithm is based on PyRosetta [16], a python script-based interface to Rosetta [17].

Thanks to the algorithm the authors were able to predict accurate protease – substrate complex structures (within 1.1 Å rms of the corresponding crystal structure) and introduced an energetic discrimination of cleavable peptides. More recently Alvizo et al. [18] employed computational methods to re-engineer a mutant PR (Pr3) more specific for one of the endogenous peptide sequences over two others.

The first aim of this study is to develop an energy-only based methodology to discern cleavable and non cleavable peptides for PRs, WT and mutant. This methodology is based on the qualitative evaluation of PR: peptide complexes binding energies and is derived from the algorithm developed by Chaudhury and Gray. The second aim is to search and define an algorithm to predict mutant PRs capable of cleaving a specific target peptide sequence different from any endogenous substrate. We use our cleavability discerning methodology on the suggested mutant proteases, in order to define the best guess in terms of specificity towards the peptide sequence. In other words, the sought after mutant structure has to show better and worse binding towards the target and endogenous peptides, respectively, than WT-PR. To the best of our knowledge ours is the first study aimed at predicting a mutant PR capable of cleaving specifically a non endogenous peptide sequence.

The paper is organized as follows: first, we present our computed binding energies for known cleavable and non-cleavable peptides bound to WT-PR, selected peptides bound to a set of single, double and triple mutants (Pr3 set) derived from Pr3 as developed by Alvizo et al., and a set of known mutant PRs and
peptide derived from drug resistance (DR set) studies [19–21].

Secondly, we present two different versions of our algorithm to determine mutant PRs that will cleave the sequence HFLSP*MIAIP, where the * symbol indicates the desired cleaving site. A discussion about the best strategy to suggest mutant enzymes follows. The conclusions summarize the main findings of the paper, followed by a detailed description of the employed computational methods.

List of Abbreviations

- **PR**: HIV-1 protease.
- **WT-PR**: Wild type HIV-1 protease.
- **mutant PR**: Mutant HIV-1 protease.
- **Pr3 set**: Set of mutant proteases derived from Pr3, a mutant protease developed by Alvizo et al. These were heterodimer proteases.
- **DR set**: Set of mutant proteases derived as a subset of HIV-1 proteases that have been found to be drug resistant. These were homodimer proteases.

Results and Discussion

Development of a Cleavability Test

In general, the activity of an enzyme towards two similar substrates is regulated by (i) the strength of the enzyme-substrate binding and (ii) the efficiency of the enzymatic reaction. The two processes are regulated by two constants, usually indicated as \( k_m \) and \( k_{cat} \), respectively. The overall enzymatic efficiency is given by the ratio of these two constants. The dynamic substrate envelope hypothesis [10] suggests that if a peptide is bound to PR it will be cleaved. Thus, we decided to evaluate the binding energy of different peptides to PR, which can be correlated to \( k_m \). We then compared the computed binding energies to PR of known cleavable and non-cleavable peptides, to be correlated to corresponding ranges of binding energies. By so doing we disregarded \( k_{cat} \), that is we did not consider possible effects from the enzymatic reaction.

The cleavability test was developed by considering binding energies of WT-PR with its endogenous and known cleavable substrates and known non-cleavable peptides. Afterwards we investigated the reliability of the test with mutant PRs (the Pr3 set) when binding PR endogenous substrates. Finally, we assessed the test on mutant PRs (the DR set) when binding mutant substrates. The complete methodology for evaluating binding energies is described in the computational methods section. In brief, it is composed by a structure optimization algorithm, followed by an energetic re-evaluation of the obtained structures. In the following paragraphs we evaluate our methodology in terms of binding energies versus cleavability for: (1) WT-PR and its endogenous substrates and known cleavable and non-cleavable peptides, (2) the Pr3 set of mutant PRs and endogenous substrates and (3) the DR set with wild type and mutated endogenous peptides. Binding energies were computed also for WT-PR and all mutant PRs in complex with octa-alanine (poly-Ala) and octa-arginine (poly-Arg) peptides to test for specific binding.

(1) Table 1 reports the computed binding energies of the set of known cleavable and non-cleavable peptides of WT-PR. The sequence of the tested endogenous cleavable peptides is reported in Table S1 in File S1. Alongside the endogenous peptides, a set of 59 known cleavable peptides was also tested. The sequence of the 59 tested non-endogenous cleavable peptides was obtained as previously described [15,22–26]. Table S5 in File S1 reports the computed binding energies to WT-PR and Table S2 in File S1 the sequences of these non-endogenous peptides. Table S6 in File S1 reports the computed binding energies of a set of peptides supposedly non-cleavable by WT-PR. The sequence of the 43 tested non-cleavable peptides was obtained as previously described [15,26,27] and is reported in Table S3 in File S1.

We performed a Mann-Whitney’s U test [28] to compare the computed binding energies, and found a significant difference between the cleavable and non-cleavable sets (\( p \approx 10^{-7} \)), as reported in Table 2. Thus, we deemed the binding energy criterion sufficient to achieve discrimination. We further analyzed the computed binding energies through an ROC plot [29] relative to different cutoff values, so as to differentiate between cleavable and non-cleavable peptides. The plot is reported in Figure 1, and the relative data in Table S11 in File S1. The computed area under ROC [30] is 0.79 and 0.80 for FMO and RosettaDock energies, respectively, being the values of 0.50 and 1.00 typical correspondingly of a useless and a perfect test. Through the ROC plot, we found the best cutoff values discriminating cleavable and non-cleavable peptides as those closest to (0, 1), which represents the theoretical perfect test. We found that cutoff values of \(-25 \text{ kcal/mol} \) and \(-3 \text{ kT} \) are best at discerning FMO and RosettaDock computed binding energies, respectively. Both FMO and RosettaDock perform well in computing binding energies capable of
discerning cleavable and non-cleavable peptides. However, Figure S1 in File S1 shows that there is no apparent correlation between FMO and RosettaDock computed binding energies. Thus, we repeated the Mann-Whitney’s U test and ROC analysis excluding the set of non-endogenous known cleavable peptides binding energies. The rationale behind this analysis is that we expect WT-PR to bind the endogenous peptides with higher affinity, as opposed to the broader range of the complete cleavable set, characterized only by cleavability and not specificity. Consequently, we assume that the endogenous peptides set have better binding energies, than the complete set of cleavable peptides. The Mann-Whitney’s U test (Table 2) shows that the RosettaDock based binding energies are in this case two orders of magnitude worse than FMO at discerning cleavable and non-cleavable peptides. The relative ROC plot (Figure S2 in File S1) shows as well that the FMO data performs better than RosettaDock, in terms of more strict best cutoff value and larger area under the ROC. Thus, we concluded that FMO computed binding energies are better than RosettaDock ones since are capable of discerning expected effects, such as the usage of a better performing subset of peptides. In the rest of this paper we will discuss only binding energies computed through FMO energy re-evaluation.

From Table 1 it is expected that WT-PR exhibits qualitatively different binding to the poly-protein substrates, given their computed binding energies ranging from −41 for the binding of p6pol-PR to −72 kcal/mol for p2-NC, with an average value of −60 kcal/mol. However, available experimental $K_m$ values [22] do not show any trend similar to the computed data. Still, one has to remember that these computed binding energies should be considered only qualitatively and only compared to others obtained in the same manner. See the Computational Methods section for further details. Furthermore, the span of both computed energies for which experimental data are available (20 kcal/mol) and the $K_m$ values (2 orders of magnitude) is too small to allow a clear trend. The computed binding energies for the set of cleavable non-endogenous peptides (Table S5 in File S1) span a wide range of values, from $-2$ to $-86$ kcal/mol, with average $-40$ kcal/mol. These peptides not being the natural target of WT-PR may account for this large span. The average computed binding energy for all cleavable peptides is $-43$ kcal/mol. The computed binding energies for the non-cleavable set of peptides (Table S6 in File S1) span an even wider range of values than those of the cleavable ones. Some PR – peptides complexes show positive energies. The majority (36%) of the computed binding energies are in the range $-35$–$0$ kcal/mol. However, a few peptides show a binding energy to WT-PR similar to those of the cleavable peptides.

(2) Recently Alvizo et al. [18] suggested through computational means a triple mutant (Pr3) with increased binding capability towards the endogenous RTp51-RTp66 cleavage sequence peptide compared to that towards other two cleavage sequences CA-p2 and p2-NC. The efficiency of Pr3 in cleaving preferentially RTp51-RTp66 was later experimentally verified. Pr3 was made by tethering a mutated chain of protease (A28S, D30F, G48R) to a wild type one. For comparison with our predicted mutant PRs, Table 3 reports our computed binding energies for the Pr3 three-mutant, as well for simpler one- and two-fold mutant PRs derived from Pr3 (Pr3 set), as compared to WT. Note, however, that experimental data are available only for the three-fold mutant Pr3. In our calculations, Pr3 set carried mutations only on chain A, while still being formed by two separate chains. We expected to find that Pr3 computed binding would be stronger towards RTp51-RTp66, while weaker towards CA-p2 and p2-NC, compared to WT-PR. The computed binding energies of the Pr3 set show that the mutant enzymes often have higher affinity for the desired RTp51-RTp66 peptide compared to CA-p2 and p2-NC. Most notably the double mutant A28S/G48R has a stronger computed binding energy towards the target peptide than WT-PR, while lower for the other two endogenous substrates. The binding energy test indicates that A28S/G48R (for which there is no experimental data available) would have been a more successful mutation than Pr3. Nevertheless, the possibility of using the binding energy test with mutant PRs was found viable.

(3) Finally we decided to apply the binding energy test to series of mutant PRs binding mutant endogenous substrates. Thus, we evaluated the binding energies of drug resistant HIV-1 proteases towards wild type and mutant substrate peptides. It has been found that mutations of the cleavage sites are correlated to mutations of the protease, often leading to drug resistance. We analyzed the K436R and A431V mutations of the NC-p1 Gag substrate peptide cleavage sequence in relation to a series of single mutations and one double mutation of HIV-1 protease (DR set). It has been reported [19] that a K436R mutation increases resistance to protease inhibitor drugs when combined with I50 V, I84 V and I84 V/L90M PR mutations, while the A431V mutation results in a more efficient PR regardless of other mutations. We expected that the more efficient mutant PR – peptide combinations were also characterized by stronger binding energies. Table 4 reports the results of our binding energy test for the DR set. Our methodology indicates cleavability for all combinations of mutant PRs and mutated NC-p1 substrate peptides. While there are some fluctuations in the binding energies, no clear pattern arises that can be related to the experimental findings. Possibly, the increased efficiency of drug resistant mutant proteases towards mutated peptides is related to $k_{cat}$. As previously stated, the effects of this constant are not considered by the present approach. Nevertheless, the binding energy test was found suitable also for combinations of mutant PRs with any peptide.

**Prediction and Analysis of Mutant PRs**

The second aim of this study was to develop a computational methodology for the design of a mutant PR. The sought after...
enzyme had to be capable of cleaving a new target substrate different from the endogenous ones. The obtained mutant PR should also be specific for the target peptide sequence compared to the endogenous peptides. The chosen sequence for the target peptide was HLSF*MAIP, where the * symbol indicates the desired cleaving site. The sequence was extracted from that of κ-casein. Once candidate mutant PRs were obtained, we employed the binding energy test to assess the enzymes cleaving capabilities. The possibility of an increase in cleaving capability towards the target substrate was asserted by differences in binding energy between WT-PR and mutant PRs. We evaluated the k

didicated as specificity determining [15] were allowed to change. The analysis of the binding energies of the mutant PRs generated by Strategy1 found the enzymes insufficient to perform the desired scope. This prompted us to further develop the algorithm. In Strategy2, the side chains of 26 residues were allowed to change. See the Computational Methods section for further details on the residues choice. The analysis of the binding energies of these mutant PRs found some of the predicted enzymes to be adequate to cleave the desired target sequence.

Tables S7 and S8 in File S1 reports the Strategy1 mutant PRs (M1–M16) and their computed binding energies towards the targetpeptide and TF-PR, CA-p2 and p2-NC endogenous peptides. Among these mutant PRs, M5 shows the strongest binding energy towards the target peptide. However it has to be noted that the computed binding energy of M5 towards the TF-PR peptide (used as a starting template for all mutant enzymes) is also stronger with respect to WT. Possibly M5 is simply a better generic binder. To verify this hypothesis we tested M5 as a binder also for other two endogenous peptide sequences, CA-p2 and p2-

| PR       | Peptides                     | RosettaDock Energy Function | FMO Energy Re-evaluation |
|----------|------------------------------|------------------------------|--------------------------|
|          | RTP51-RTp66                  | poly-Ala                     | poly-Arg                 | TF-PR        | CA-p2        | p2-NC       |
| WT-PR    | −68                          | −15                          | −41                      | −62          | −52          | −72         |
| Single mutant |                             |                              |                          |              |              |             |
| A28S     | −65                          | −12                          | −35                      | −41          | −13          | −67         |
| D30F     | −48                          | −1                           | 0                        | −7           | −4           | −43         |
| G48R     | −66                          | −44                          | −27                      | −55          | −15          | −43         |
| Double mutant |                             |                              |                          |              |              |             |
| A28SD30F | −44                          | −16                          | 30                       | −35          | −22          | −55         |
| A28SG48R | −96                          | −16                          | −54                      | −35          | −14          | −60         |
| D30FG48R | −76                          | 3                            | 18                       | −19          | −1           | −54         |
| Triple mutant |                             |                              |                          |              |              |             |
| A28SD30FG48R | −42                        | −21                          | 12                       | −32          | −12          | −63         |

Table 3. FMO computed binding energies of HIV-1 protease WT and Pr3 set of mutant PRs.

Computed binding energies (kcal/mol) of WT and mutant HIV-1 protease in complex with RTP51-RTp66, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides. doi:10.1371/journal.pone.0095833.t003

Table 2. Comparison of WT-PR computed binding energies.

|                  | RosettaDock Energy Function | FMO Energy Re-evaluation |
|------------------|-----------------------------|--------------------------|
| Average endogenous | −6 (kT)                    | −60 (kcal/mol)           |
| (Standard deviation) | (3) (kT)                  | (10) (kcal/mol)          |
| Average all cleavable | −5 (kT)                  | −43 (kcal/mol)           |
| (Standard deviation) | (3) (kT)                  | (22) (kcal/mol)          |
| Average non cleavable | −1 (kT)                  | −15 (kcal/mol)           |
| (Standard deviation) | (4) (kT)                  | (28) (kcal/mol)          |
| U test probability (all cleavable VS non-cleavable) | 1.46 × 10⁻² | 2.21 × 10⁻⁷ |
| U test probability (only endogenous VS non-cleavable) | 3.49 × 10⁻⁴ | 6.16 × 10⁻⁶ |

*Table 1.  †Table 1 plus Table S5 in File S1.  ‡Table S6 in File S1.
NC. Compared to WT-PR, M5 has weaker binding energy for the former peptide, but equal for the latter. In conclusion, M5 is not predicted to be more specific for the target sequence than for the endogenous peptides. Moreover, M5 was not directly predicted through Strategy1, but as a homodimeric derivative of M2, which shows only a small improvement in binding of the target peptide. All other mutant PRs suggested by Strategy1, M1–M4 and M6–M16, were found having a weak binding energy towards the target peptide, with some of them showing prominently positive binding energies. It can be concluded that Strategy1 is unsatisfactory at predicting a mutant PR with an increased and specific affinity towards the target peptide. This is possibly due to the fact that allowing only six residues to change is too strict a condition to achieve a suitable mutant PR.

Thus, we decided to further improve the mutation algorithm by including more residues among those that can be changed. The six generations of mutant PRs computed through our Strategy2 mutant algorithm are presented in Table 5. We refer to them as generations of mutant PRs computed through our Strategy2 allowing only six residues among those that can be changed. The six generations of mutant proteases, at last M24,–M24 should retain the main structural features of the wild type enzyme. We also tried to analyze the choice of changed residues. Figure 3 shows that the residues that were changed from WT-PR to M24 were disposed all around the bound peptide. Although it is evident that the A28S substitution on chain A introduces a hydrogen bond between the residue and the side chain of the serine in the peptide (Figure S3 in File S1), the other substitutions are less easily rationalized. On going study aims at elucidating the role of the other residues substitutions.

It is interesting to note that Strategy2 mutated only 7 out of the 26 residues that were set as mutable in the method. It is also worth noting that of the 7 residues (A28, D30, K45, I50, P81, V82, I84) suggested by Strategy2 in the various mutant generations, A28, K45, P81 are not included in the set of major mutations site of HIV-1 protease responsible for drug resistance [31], that is: D30, V32, M46, I47, G48, I50, I54, Q58, T74, L76 V82, N83, I84, N88, L90, A28, K45, and P81 together with I50 are also not included in the specificity determining residues set [15]. However, A28 was located by Alvizo et al. for the Pr3 mutant [18]. We envision Strategy2 also as a tool to locate those residues most involved in binding a given substrate peptide.

From the analysis of the different PRs, mutant and wild type, and their binding energies, it is worth to note that WT-PR has a certain affinity with the octa-arginine peptide. Its computed binding energy is at the limit to consider the octa-arginine peptide as cleavable by WT-PR. Possibly this relatively strong binding is given by very few interactions. Accordingly, the single D30F change on chain A, that is changing one negatively charged residue into an aromatic hydrophobic one, is able to drop the computed binding energy to 0, as shown in Table 4. The currently going analysis of the residue by residue interactions for the modified side chains will give further information also on this aspect of the binding of PR.

Finally, it is interesting to note that the algorithm is not always preserving amino acid side chain changes through the generations. For example, I84 V on chain A is introduced in M18 and kept in M19, M20 and M21, but later reverted. Possibly, an isoleucin in position 84 is energetically more favorable, given the other side chain changes.
Conclusions

In the first part of this study we developed a methodology to test the cleavability of a peptide by HIV-1 protease (Tables 1 and S6 in File S1), solely based on the binding energy between the enzyme and the substrate. The methodology can also be applied to mutant PRs, Table 3. The technique is based on a PyRosetta algorithm generating, iteratively, optimized structures, coupled with an energy re-evaluation at a higher level of theory (FMO/PCM MP2/6-31G(d)).

In the second part of this study, the optimization algorithm was extended to permit the stochastic change of the side chain of selected residues, in order to better bind a given target peptide sequence. The selected target peptide was required to be different from the endogenous peptides. The desired outcome was a mutant PR with stronger and weaker predicted binding energy for the target and endogenous peptides, respectively, compared to WT-PR. The mutant PRs M22 and M24 generated through Strategy2 exhibit such desired characteristics (Table 6). We analyzed the backbone structure of WT-PR and M24 and found no major differences, thus indicating that M24 should retain the general structure features of wild type HIV-1 protease. Strategy2 algorithm is able to predict mutations outside the usual set of residues involved in drug resistance, possibly giving an ulterior insight into the binding process of HIV-1 protease.

Ongoing experimental studies will show if and how well M22 and/or M24 bind and cleave the target sequence. Our current experimental and computational studies are also aimed at analyzing M24 mutations, residue by residue and in combination, and their possible role in binding the target sequence. It is our hope that the experimental tests will provide enough information to be used to further improve the mutant generating algorithm. If the combination of computational algorithm and experimental verification is successful it will maybe permit the design of mutant PRs specific for any given substrate peptide.

Computational Methods

In general, the activity of an enzyme towards two similar substrates is regulated by (i) how good the enzyme-substrate binding is and (ii) how efficient the enzymatic reaction is. Following the dynamic substrate envelope hypothesis [9,10], we

### Table 5. Strategy2 suggested mutant PRs.

| Mutant ID | Chain A | Chain B | Mutation Scheme | Notes |
|-----------|---------|---------|----------------|-------|
| M17       | A28S D30T | A28S D30T K45M I50L V82F | F | After one mutation step |
| M18       | A28S D30T I50L P81D V82R I84V | A28S D30T K45M I50L V82Y | F | After one mutation step |
| M19       | A28S D30T I50L P81D V82R I84V | A28S D30T K45A I50L V82Y I84L | F | After two mutation steps |
| M20       | A28S D30T I50L P81D V82R I84V | A28S D30T K45D I50L V82Y I84L | F | After three mutation steps |
| M21       | A28S D30T I50L P81L V82Y I84V | A28S D30T K45D I50L V82Y | F | After four mutation steps |
| M22       | A28S D30T I50L P81L V82Y | A28S D30T K45A I50L V82Y | F | After five mutation steps |
| M23       | A28S D30T I50L P81L V82Y | A28S D30T K45A I50L V82Y | F | After six mutation steps |
| M24       | A28S D30T K45A I50L P81L V82Y | A28S D30T K45A I50L P81L V82Y | – | Homodimer of M22 |

M17–M23 represent the subsequent generations of mutant PRs suggested by Strategy2. All mutant enzymes were generated following Scheme F. doi:10.1371/journal.pone.0095833.t005

### Table 6. FMO computed binding energies of HIV-1 protease WT and Strategy2 mutant PRs.

| PR   | Peptides | Target | poly-Ala | poly-Arg | TF-PR | CA-p2 | p2-NC |
|------|----------|--------|----------|----------|-------|-------|-------|
| WT-PR|          | –9     | –15      | –41      | –62   | –52   | –72   |
| Gen 1 | M17      | –34    | –13      | –47      | –68   | –82   | –74   |
| Gen 2 | M18      | –24    | –19      | –45      | –82   | –62   | –63   |
| Gen 3 | M19      | –17    | 2        | 1        | –67   | –46   | –81   |
| Gen 4 | M20      | –23    | –2       | –19      | –67   | –33   | –84   |
| Gen 5 | M21      | –20    | 2        | 7        | –37   | –32   | –18   |
| Gen 6 | M22      | –29    | –6       | 10       | –42   | –25   | –30   |
| Gen 7 | M24      | –29    | –11      | 7        | –44   | –33   | –33   |

Computed binding energies (kcal/mol) of WT-PR and Strategy2 mutant proteases in complex with Target, poly-alanine, poly-arginine, TF-PR, CA-p2 and p2-NC peptides. doi:10.1371/journal.pone.0095833.t006
assume a correlation between the binding of different peptides to PR and cleavability of the former. Thus we compute qualitative binding energies, on the premise that lower binding energy equals better cleavability.

**Binding Energies**

**PyRosetta Algorithm.** The structure of wild type (WT) HIV-1 protease in complex with different octa-peptides was optimized using PyRosetta 1.1 [16], a python script-based interface to Rosetta [17], and the algorithm depicted in Figure 4. The algorithm is based on the flexible peptide-docking algorithm used by Chaudhury and Gray [15] to identify in WT HIV-1 protease the active-site residues mostly involved in the discrimination of cleavable and non-cleavable peptides. Following their algorithm, the HIV-1 protease – peptide complexes are represented in atomic resolution, as opposed to a coarse-grain representation. With respect to the algorithm described in [15], our algorithm (Figure 4) has a larger number of cycles (8 x 4 x 6 = 192 compared to 8 x 12 = 96), and more ‘small’ and ‘shear’ moves for the perturbation of both the side chain and the backbone atoms. The side chain conformations are further optimized through a repacking algorithm [32] and using the extended Dunbrack library [33,34]. The moves are applied to all residues of the substrate peptide plus a selected number of residues of the protease, with the following criterion: all residues inside a 5 A distance from any atom of the substrate peptide, plus all the residues reported as active by Chaudhury and Gray [15], plus their ± 1 neighbours, plus if one residue is included on only one chain it is made to be included in both. After the moves, an energy minimization step is performed, based on the Davidon-Fletcher-Powell method [35,36]. Each structure is then accepted or rejected based on a Monte Carlo (MC) criterion depending on the standard RosettaDock energy function [32,33,37–39]. Along the optimization a temperature gradient was applied, from an initial value of K = 3.0 to 1.0, unless differently stated. 500 decoy structures were generated using 5 parallel algorithm runs, each producing 100 structures.

The main difference with the algorithm of [15] is that after the algorithm produced 500 decoy structures, the lowest in energy is chosen and used as a starting structure for another cycle of optimization. This process is repeated K times, until convergence. It was found that, after at least 5 cycles, the computed RosettaDock energy did not change between subsequent cycles as soon as all 5 parallel runs of a single cycle produced structures with the same energy. Consequently, in order to render as automatic as possible the algorithm, the fact that K = 5 and that each parallel run produced, as best structure, a decoy with the same energy was taken as a mark for convergence. It was found that, on average, a value of K = 20 was sufficient. As an example, Figure 5 reports the energy of WT-PR bound to TF-PR along the optimization. The points at each step corresponds to the RosettaDock energy of the lowest in energy decoy out of the 500 computed at that particular step. Such structure would then be used as starting point for the next cycle. At the end of the K cycles the lowest in energy decoy is chosen as the PyRosetta optimized structure.

The same algorithm was also used for the optimization of mutant HIV-1 proteases (side info), the octa-peptides alone, and the protease alone as apo-enzyme.

The starting structures were prepared from that of HIV-1 protease in complex with an inhibitor (PDB accession code 1HXB [40]), considered as apo-protein. In order to place the substrate peptide, the structure of a D25N deactivated protease in complex with the natural substrate peptide p2-NC (PDB accession code 1KJ7 [9]) was aligned with respect to the backbone atoms of the protease (RMS = 0.436 Å). The starting structure was then composed using the apo-protein from 1HXB and the substrate peptide from 1KJ7. All subsequent protease-peptide complexes were created starting from this structure and mutating the peptide accordingly. See Tables S1, S3 and S4 in File S1 for a complete list of the considered substrate peptides. Hydrogen atoms were added through the program PyMol [41].

**Further Structures Optimization and Energetic Re-evaluation.** The position of the hydrogen atoms of each PyRosetta generated structure was optimized using Open Babel [42] with the MMFF94 [43–47] force field. The energy of each structure was finally re-evaluated at the higher level of theory ‘FMO2-MP2/6-31G(d)/PCM [1]’. Single point energy evaluations were carried out using the fragment molecular orbital (FMO) approximation [48,49], as implemented in GAMESS [50]. Each FMO calculation was carried out at the MP2 level of theory [51] with the 6–31G(d) basis set [52,53] and the Polarizable Continuum Model (PCM) approximation [34,55]. Pairs of fragments separated by more than two van der Waals radii were calculated using a Coulomb expression for the interaction energy and ignoring correlation effects (RESPDIM = 2.0, RCORESD = 2.0 in $FMO)$. The input files for the FMO calculations were prepared using the program FRAGIT [56].

**Binding Energies Evaluation.** The re-evaluated energy of every optimized structure was used to compute the binding energy of PR with different substrate peptides. The binding energy (E_{\text{Bind}}) of HIV-1 protease (wild type or mutated) and a peptide was evaluated with equation (1), where E_{\text{Complex}} is the energy of the complex, E_{\text{APO}} the energy of the protease optimized as apo-protein, E_{\text{Pep}} the energy of the optimized peptide.

\[
E_{\text{Bind}} = E_{\text{Complex}} - (E_{\text{APO}} + E_{\text{Pep}})
\]  

These binding energies can not be directly compared to experimental values, for which a much more complex and accurate methodology is required [57]. These energies were used only to qualitatively compare different PR – peptide combinations.

**Mutation Algorithm**

A similar procedure as that described in Figure 4 was used to produce mutant HIV-1 proteases, possibly capable of cleaving a given peptide different from the endogenous substrate peptides. The general idea was to ‘expose’ the protease to a different peptide...
and allow some residues to change in order to accommodate it better. A target octa-peptide was chosen: HLSF*MAIP, where the * symbol indicates the desired cleaving site. The peptide sequence was extracted from that of \( \kappa \)-casein.

The assumption behind the algorithm is that lowering the energy of the PR – peptide complex by changing the side chains of selected residues would decrease also the binding energy, thus increasing the cleavability.

Two different methodologies were designed to predict mutant PRs, Strategy1 and Strategy2. The Strategy1 mutation algorithm is depicted in Figure 6. Each optimization step corresponds to the algorithm of Figure 4. In the mutation steps (also based on the previous algorithm), the Dunbrack library of rotamers includes all rotamers of all amino acids, but only for a selected number of residues. The six specificity determining residues, as found by [15], are chosen to be altered. In other words, during the mutation step, whenever one of the alterable residues is being optimized, the random choice of a test rotamer is among all possible amino acids. In Scheme A alterations are allowed on all 6 residues on both chains, for a total of 12 alterable residues. Thus, side-chain perturbation and repacking rotamer choice is performed randomly selecting among \( 12 \times 20 = 240 \) possible amino acids. In Scheme B only alterations on L76 and V82 of Chain A and D30, I47, G48, and I84 of Chain B are allowed, for a total of 6 alterable residues.
In this case, side-chain perturbation and repacking rotamer choice is performed with a random selection among 6×20 = 120 possible amino acids. Each mutation step took ca. 40 hours on 5 cpus to produce 500 decoys. The lowest energy decoy is then chosen as starting structure for the next step. The energy of the structure is evaluated with the standard RosettaDock energy function. The residue reference energy part of the energy function [32] takes into account also the differences between different amino acids. In other words, energy differences between two mutant structures originates solely from different side chain interactions rather than from a different number of atoms.

Both the mutation and the optimization steps were repeated \( K \) and \( K' \) times, respectively. The mutation cycles are considered converged once two following cycles do not introduce new mutations. Different values of \( K \) and \( K' \) were found necessary to reach convergence. After a series of mutation cycles (\( K' \geq 8 \)), a series of optimization cycles was performed (\( K \leq 3 \)), followed by another usually shorter mutation cycle (\( K' \leq 3 \)) and finally a short optimization cycle (\( K \leq 3 \)).

Among the naturally cleaved peptides, TF-PR (sequence SFN*PTQIT) was chosen as a starting substrate peptide, since it is the most similar, in terms of conserved residues, to the target peptide (sequence HLS*MAIP). Consequently, the optimized structure of WT protease in complex with the TF-PR peptide was chosen as starting template. The substrate peptide sequence was altered one amino acid at the time, as reported in Table S10 in File S1. After each peptide alteration, a series of protease mutation and optimization cycles were performed. Once convergence was reached, a new peptide single amino acid change was introduced and the procedure repeated. Different mutant PRs were obtained from different runs by changing a few parameters, e.g. the initial temperature of the simulation. These parameters are specified in Table S7 in File S1. Some mutant PRs were also produced by ‘exposing’ the protease directly to the target peptide without prior intermediates (mutation Scheme F). This last process required a higher number of \( K \) cycles (\( K \geq 15 \)), but without having to cycle through one substrate peptide residue at the time.

All mutant PRs obtained through Strategy1 were heterodimers. By simply equalizing alterations on both chains a number of extra homodimer mutant PRs were also obtained. These structures were subsequently optimized as previously described.

In Strategy2 the number of residues allowed to change was increased in order to include all amino acids residing inside a 3 Å radius from the TF-PR peptide. In other words, we chose those residues with at least one atom that is distant at most 3 Å from any atom of the substrate peptide. The specificity determining residues were also included in the set of alterable amino acids, if not already present. The residues Asp25, Thr26 and Gly27 of both chains were excluded from the set, since they represent the catalytic triad [5]. The full set of 26 residues is reported in Table S9 in File S1. Thus, side-chain perturbation and repacking rotamer choice is performed randomly selecting among 26×20 = 520 possible amino acids. The mutant PRs were generated using the target peptide directly (Scheme F). Each mutation step took a bit more than 3 days on 5 cpus to produce 500 decoy structures. An initial temperature of 9 Kf was used. \( K = 6 \) mutation cycles were performed. The lowest in energy decoy after each mutation step was subsequently optimized (two after the first step). The sixth mutation step did not introduce any new mutation in PR and the mutation cycle was stopped.

Figure 4. PyRosetta based optimization algorithm. \( \phi, \psi, \chi \) represent perturbations applied to both backbone and side chain dihedral angles. MC criterion stands for a Monte Carlo based check of decoy structures.

doi:10.1371/journal.pone.0095833.g004

Figure 5. Optimization algorithm convergence. Example of energy convergence during the various macro cycles of the optimization algorithm for WT-PR in complex with TF-PR peptide. Each point along the graph corresponds to the energy (computed with the RosettaDock energy function) of the lowest in energy decoy out of 500 produced during each of the \( K \) steps.

doi:10.1371/journal.pone.0095833.g005

Figure 6. PyRosetta based mutation algorithm. The optimization step is the algorithm presented in Figure 4. In the mutation step the side chain perturbation for the six specificity determining residues is among all possible rotamer of all 20 amino acids.

doi:10.1371/journal.pone.0095833.g006
Also the mutant PRs obtained through Strategy2 were heterodimers. Only the homodimer of the final mutant PR was considered, see Table 3.

Supporting Information

File S1

Tables S1–S11, Figures S1–S14, a movie showing the three dimensional structure of WT-PR bound to the target peptide, with highlighted the residues that are changed in M24.

References

1. Rao MB, Tanksale AM, Ghate MS, Deshpande VV (1998) Molecular and Biotechnological Aspects of Membrane Proteases. Microbiology and Molecular Biology Reviews 62: 597–635.
2. Gupta R, Beg Q, Lorenz P (2002) Bacterial alkaline proteases: molecular aspects and industrial applications. Applied Microbiology and Biotechnology 59: 15–32.
3. Li Q, Yi L, Marx P, Iverson BL (2013) Commercial proteases: Present and future. FEBS Letters 587: 1155–1163.
4. van Beilen JB, Li Z (2002) Enzyme technology: an overview. Current Opinion in Biotechnology 13: 338–344.
5. Brik A, Wong CH (2003) HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 1: 5–14.
6. Navia MA, Fitzgerald PMD, McKeever BM, Leu CT, Heimbach JC, et al. (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337: 615–620.
7. Wlodawer A, Miller M, Jaskolski M, Sathynarayana B, Baldwin E, et al. (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245: 616–621.
8. Davies DR (1990) The Structure and Function of the Aspartic Proteases. Annual Review of Biophysics and Biophysical Chemistry 19: 189–215.
9. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA (2002) Substrate Shape Determines Specificity of Recognition for HIV-1 Protease: Analysis of Crystal Structures of Six Substrate Complexes. Structure 10: 369–381.
10. Ozen A, Haliloglu T, Schiffer CA (2011) Dynamics of Preferential Substrate Recognition in HIV-1 Protease: Redefining the Substrate Envelope. Journal of Biochemical and Biophysical 61: 397–407.
11. Perez MAS, Fernandes PA, Ramos MJ (2010) Substrate Recognition in HIV-1 Protease: A Computational Study. The Journal of Physical Chemistry B 114: 12923–12932.
12. Sherman W, Tidor B (2008) Novel Method for Probing the Specificity Binding Profile of Ligands: Applications to HIV Protease. Chemical Biology & Drug Design 71: 387–407.
13. Ozen A, Haliloglu T, Schiffer CA (2011) Dynamics of Preferential Substrate Recognition in HIV-1 Protease: Redefining the Substrate Envelope. Journal of Biochemical and Biophysical 61: 397–407.
14. Lemmon G, Kaufmann K, Meiler J (2012) Prediction of HIV-1 Protease/Inhibitor Affinity using Rosetta-Ligand. Chemical Biology & Drug Design 79: 680–696.
15. Chaudhury S, Gray JJ (2009) Identification of Structural Mechanisms of HIV-1 Protease Specificity Using Computational Peptide Docking: Implications for Drug Resistance. Structure 17: 1636–1648.
16. Chaudhury S, Lyskov S, Gray JJ (2010) PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics 26: 869–691.
17. Kauffman KW, Lemmon GH, DeLuca SL, Sheehan JH, Meiler J (2010) Pracitically Useful: What the Rosetta Protein Modeling Suite Can Do for You. Biochemistry 49: 2967–2980.
18. Alvizo O, Mittal S, Mayo SL, Schiffer CA (2012) Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Protein Science 21: 1029–1041.
19. Kolli M, Stawiski E, Chappey C, Schiffer CA (2009) Human Immunodeficiency Virus Type 1 Protease: A Computational Study. The Journal of Physical Chemistry B 114: 6–14.
20. Ozen A, Haliloglu T, Schiffer CA (2012) HIV-1 Protease and Substrate Cleavage Validates the Substrate Envelope As the Substrate Recognition Pattern. Journal of Chemical Theory and Computation 8: 703–714.
21. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA (2004) Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-Protease Correlated Cleavage Spot with a VÎ2A Drug-Resistant Mutation in Viral Protease. Journal of Virology 78: 12446–12454.
22. Tozer J, Blaha I, Copeland TD, Woudراك EM, Orozlan S (1991) Comparison of the HIV-1 and HIV-2 proteases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Letters 281: 77–80.
23. Rivière Y, Blunk V, Kourilsky P, Israel A (1991) Processing of the precursor of NF-kB by the HIV-1 protease during acute infection. Nature 350: 625–626.
24. Oswald M, von der Helm K (1991) Fibronectin is a non-viral substrate for the HIV protease. FEBS Letters 292: 298–300.
25. Tomaselli AG, Sarich JL, Barrett J, Bearden MD, Howe WJ, et al. (1993) Human immunodeficiency virus type 1 reverse transcriptase and ribonuclease h as substrates of the viral protease. Protein Science 2: 2167–2176.
26. Chou KC (1996) Prediction of Human Immunodeficiency Virus Protease Cleavage Sites in Proteins. Analytical Biochemistry 233: 1–14.
27. Mann HR, Whitney DR (1947) On a Test of Whether One of Two Random Variables is Stochastically Larger than the Other. The Annals of Mathematical Statistics 18: 50–60.
28. Metz CE (1978) Basic principles of (ROC) analysis. Seminars in Nuclear Medicine 8: 283–288.
29. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29–36.
30. Johnson VA, Calvez V, Gounard HE, Paredes R, Pillay D, et al. (2013) Update of the Drug Resistance Mutations in HIV-1: March 2013. Top Antive Med 21: 6–14.
31. Kuhlmian B, Baker D (2000) Native protein sequences are close to optimal for their structures. Proceedings of the National Academy of Sciences of the United States of America 97: 10383–10386.
32. Dunbrack RL, Cohen FE (1997) Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Science 6: 1661–1681.
33. Wang G, Schuerer-Furman O, Baker D (2005) Improved side-chain modeling for protein-protein docking. Protein Science 14: 1329–1339.
34. Dunbrack RL, Cohen FE (1997) Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Science 6: 1661–1681.
35. Tomaszek TA, Moore ML, Strickler JE, Sanchez RL, Dixon JS, et al. (2013) Update of the Drug Resistance Mutations in HIV-1: March 2013. Top Antive Med 21: 6–14.
36. Wlodawer A, Miller M, Jaskolski M, Sathynarayana B, Baldwin E, et al. (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245: 616–621.
37. Chaudhury S, Lyskov S, Gray JJ (2010) PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics 26: 869–691.
38. Kaufmann KW, Lemmon GH, DeLuca SL, Sheehan JH, Meiler J (2010) Practically Useful: What the Rosetta Protein Modeling Suite Can Do for You. Biochemistry 49: 2967–2980.
39. Alvizo O, Mittal S, Mayo SL, Schiffer CA (2012) Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Protein Science 21: 1029–1041.
40. Kolli M, Stawiski E, Chappey C, Schiffer CA (2009) Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enable Inhibitor Resistance. Journal of Virology 83: 11027–11032.
41. Ozen A, Haliloglu T, Schiffer CA (2012) HIV-1 Protease and Substrate Cleavage Validates the Substrate Envelope As the Substrate Recognition Pattern. Journal of Chemical Theory and Computation 8: 703–714.
42. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA (2004) Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-Protease Correlated Cleavage Spot with a VÎ2A Drug-Resistant Mutation in Viral Protease. Journal of Virology 78: 12446–12454.
43. Tozer J, Blaha I, Copeland TD, Woudtrak EM, Orozlan S (1991) Comparison of the HIV-1 and HIV-2 proteases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Letters 281: 77–80.
44. Riviere Y, Blunk V, Kourilsky P, Israel A (1991) Processing of the precursor of NF-kB by the HIV-1 protease during acute infection. Nature 350: 625–626.

Acknowledgments

Computational resources were provided by the Danish Center for Scientific Computing (DCSC). LDV acknowledges S. Chaudhury and J. Gray for fruitful discussions about PyRosetta, for providing the set of non cleavable peptides and a copy of their algorithm script. C. Steinmann is acknowledged for help with the program FRAGIT and the FMO based calculations.

Author Contributions

Conceived and designed the experiments: JHJ LDV. Performed the experiments: LDV. Analyzed the data: JHJ MW JRW LDV. Wrote the paper: JHJ LDV.

PLOS ONE | www.plosone.org 10 May 2014 | Volume 9 | Issue 5 | e95833
49. Fedorov DG, Kitaura K (2007) Extending the Power of Quantum Chemistry to Large Systems with the Fragment Molecular Orbital Method. The Journal of Physical Chemistry A 111: 6904–6914.

50. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, et al. (1993) General atomic and molecular electronic structure system. Journal of Computational Chemistry 14: 1347–1363.

51. Fedorov DG, Kitaura K (2004) Second order Møller-Plesset perturbation theory based upon the fragment molecular orbital method. The Journal of Chemical Physics 121: 2493–2499.

52. Hariharan PC, Pople JA (1973) The influence of polarization functions on molecular orbital hydrogenation energies. Theoretical Chemistry Accounts: Theory, Computation, and Modeling (Theoretica Chimica Acta) 28: 213–222.

53. Francl MM, Pietro WJ, Hehre WJ, Binkley JS, Gordon MS, et al. (1982) Selfconsistent molecular orbital methods. XXIII. A polarization-type basis set for second-row elements. The Journal of Chemical Physics 77: 3654–3665.

54. Tomasi J, Mennucci B, Camanni R (2005) Quantum Mechanical Continuum Solvation Models. Chemical Reviews 105: 2999–3094.

55. Fedorov DG, Kitaura K, Li H, Jensen JH, Gordon MS (2006) The polarizable continuum model (PCM) interfaced with the fragment molecular orbital method (FMO). Journal of Computational Chemistry 27: 976–985.

56. Steinmann C, Ibsen MW, Hansen AS, Jensen JH (2012) FragIt: A Tool to Prepare Input Files for Fragment Based Quantum Chemical Calculations. PLoS ONE 7: e44480.

57. Genheden S, Kongsted J, Sønderhøj P, Ryde U (2010) Nonpolar Solvation Free Energies of Protein–Ligand Complexes. Journal of Chemical Theory and Computation 6: 3558–3568.